🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Valeant appoints Ari Kellen executive vice president

Published 2016-03-02, 10:55 p/m
© Reuters.  Valeant appoints Ari Kellen executive vice president
PSON
-
BHC
-

March 2 (Reuters) - Valeant Pharmaceuticals (NYSE:VRX) International
Inc VRX.N VRX.TO said it appointed Ari Kellen executive vice
president, succeeding Deb Jorn who has resigned, effective
immediately.
Eric Abramson, vice president of dermatology and immunology
marketing, has been appointed general manager of the U.S
dermatology business, the Canadian drugmaker said in a statement
on Wednesday.
Valeant disclosed on Monday that the U.S. Securities and
Exchange Commission is investigating the company's relationship
with Philidor RX Services and also said it would delay filing
its annual report beyond the 15-day extension period.

Valeant Chief Executive Michael Pearson (LON:PSON) returned from a
prolonged medical leave, and the company has canceled the
release of its fourth-quarter earnings and withdrew its 2016
financial guidance.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.